7 Transformational Retreats That Reboot Body, Mind, And Soul
Wellness travel has matured. It's no longer about brief escapes or surface-level fixes. These retreats are structured to identify core imbalances. Whether physiological, hormonal, or neurological - and support the body in recovering energy, clarity, and emotional stability. Across Europe, Asia, and the Americas, the following destinations are taking a science-backed, experience-driven approach to what it means to truly restore.
VIVAMAYR Maria Wörth, Austria
VIVAMAYR Maria Wörth continues to lead in functional detox and gut regeneration. Located at the edge of Lake Wörthersee in southern Austria, the clinic blends clinical diagnostics with integrative therapies rooted in Mayr Medicine. Guests begin with full blood panels, food intolerance testing, and mineral analysis, followed by a customised treatment plan that may include manual abdominal treatments, oxygen therapy, micronutrient supplementation, and liver compresses.
VIVAMAYR - Precision Gut Health and Diagnostics on the Lake
In 2025, the focus has shifted toward metabolic flexibility and cellular longevity. New protocols support hormonal recalibration—particularly for midlife transitions and adrenal fatigue. Meals follow a strict alkaline principle, with carefully controlled food combinations and chewing rituals that support digestive rest. The lakeside calm, absence of overstimulation, and attentive medical team make this retreat ideal for those navigating burnout, low-grade inflammation, or chronic fatigue.
La Réserve Ramatuelle, France
Just minutes from Saint-Tropez but buffered by pine trees and sea views, La Réserve Ramatuelle offers high-level wellness in a discreet Mediterranean setting. Their Better Aging programs are developed with Nescens, the Swiss anti-aging clinic known for evidence-based preventive health. This is not a spa break—it's a calibrated combination of cellular nutrition, movement science, and aesthetic medicine.
La Reserve Ramatuelle - Structured Longevity on the Côte d'Azur
Guests begin with biological age testing, body composition scans, and consultations to assess stress markers, inflammation, and posture. Treatments include osteopathy, lymphatic drainage, facial radiofrequency, and strength conditioning. The latest addition is a neuro-resilience track: cold immersion, sleep cycle training, and guided breathing aimed at increasing stress tolerance and resetting the autonomic nervous system. Ideal for anyone navigating performance pressure or cognitive fatigue.
Lanserhof Sylt, Germany
On Sylt, the North Sea island often described as Germany's answer to the Hamptons, the Lanserhof Group has built a beautiful clinic designed for people who need a break - but not in the traditional sense. There's no spa playlist, no welcome champagne. Instead: intake forms, lab diagnostics, and a structured medical program from day one.
At the heart of it is the Lanserhof Cure, a fasting method developed over decades. Meals are warm, minimal, and functional: think vegetable broths, steamed root vegetables, digestible proteins. It's designed to reduce inflammation, regulate digestion, and reset metabolic rhythms. Meals are served slowly and mindfully, often with instructions on how long to chew.
Lanserhof Sylt -
Their state of the art Longevity Programme goes far beyond nutrition. It starts with comprehensive diagnostics, including bioimpedance analysis, HRV (heart rate variability), metabolic checks, fatty liver scans, and blood work focused on the biological signs of aging. Based on these results, guests follow a personalized plan that may include detox drainage therapy, abdominal treatments, cryotherapy, ozone therapy, infusions, and cell gym training designed to improve mitochondrial function.
Movement and recovery are part of the daily schedule: guided exercise, relaxation sessions, craniosacral therapy, massages, and breathwork. All of it is medically supervised and adjusted throughout the stay.
The Women's Health Programme runs parallel, addressing hormone imbalances, cycle irregularities, menopause, and stress-related symptoms. It includes specialist gynaecological check-ups, hormone labs, targeted infusions, nutrition planning, and emotional health support.
What makes Sylt unique is its environment. The coastal air is naturally high in iodine and oxygen, conditions that have long been used for respiratory treatment in Germany. For guests recovering from long COVID, fatigue, or burnout, this becomes a key part of the therapy. Lanserhof Sylt isn't relaxing in the usual sense. But for many, that's exactly the point. It's a full system reset - clinical, controlled, and focused on results.
Six Senses Crans-Montana, Switzerland
Six Senses Crans-Montana is situated at altitude, above the village of Crans. The resort merges clinical-grade diagnostics with movement, nature immersion, and circadian recalibration. The air is pure, the views wide, and the pace structured yet nurturing.
The wellness centre offers hyperbaric oxygen chambers, infrared saunas, IV therapy, and a fascia release lab. The Biohacking Suite includes PEMF mats, lymphatic boots, red light panels, and binaural frequency chairs. Room lighting mimics the natural light spectrum, helping reset the body's internal clock.
Six Senses Crans Montana - Alpine Biohacking
This resort regularly hosts significant retreats such as a family-focused resilience week led by Ben Greenfield, and 'Alma Frequency,' a festival of longevity experts, somatic therapists, and consciousness teachers. Guests often arrive exhausted or overstimulated—and leave with better sleep, rebalanced hormones, and improved mental clarity.4.
JOALI BEING, Maldives
JOALI BEING is entirely focused on transformation. Located in the Raa Atoll, accessible only by private seaplane, it was designed as the Maldives' first fully dedicated wellbeing island. Every guest is assigned a bespoke program aligned with one of four pillars: mind, microbiome, skin, or energy.
The diagnostic process includes biometric screening, epigenetic testing, and consultations across multiple healing systems. Treatments range from cryotherapy and IV drips to sound resonance therapy, Ayurvedic protocols, and hormone-optimised nutrition. The culinary concept avoids blood sugar spikes, gluten, and inflammatory ingredients. Daily programming integrates breathwork, movement, and hydrotherapy. Each structure on the island has been built according to sacred geometry, reinforcing energetic coherence.
JOALI BEING - A Wellness-Only Island
Life transitions, nervous system dysregulation, trauma recovery—guests come for various reasons, but leave with the same result: a sense of regulation, clarity, and restored vitality. 2025 brought new immersive residencies with visiting practitioners in neuroscience, trauma release, and spiritual psychology.
RAKxa Wellness, Bangkok, Thailand
On a small island in Bangkok's lush Green Lung, RAKxa offers a medical-grade reset within an immersive natural environment. A joint venture with Bumrungrad International Hospital, the centre is known for its detailed testing and integrative protocols.
Each stay starts with full diagnostics: blood labs, metabolic rate, cardiovascular testing, and a gut flora profile. Based on results, a medical team builds a treatment plan that can include acupuncture, IV therapy, Ayurvedic oil work, breath training, cryotherapy, and Thai herbal protocols.
RAKxa, Bangkok, Thailand - Functional Medicine with Thai Healing Heritage
2025 introduced a new hormonal reset program, especially popular among women navigating perimenopause and fatigue. The program combines sleep tracking, adaptogenic herbal support, lymphatic drainage, and nutritional mapping. Guests appreciate the clear structure, high medical standards, and respectful integration of Eastern modalities.
AZULIK, Tulum, Mexico
AZULIK offers something many retreats don't: space to return to intuition. Built without electricity, straight lines, or digital interference, the jungle-side retreat invites guests into a completely analog experience. Architecture is rooted in Mayan cosmology, and everything is designed to create stillness—no artificial light, no screens, no noise.
Daily rhythms are centred around ceremonial practices: cacao journeys, temazcal (sweat lodge), jungle meditation, and fire rituals. Sound journeys take place under the stars. Meals are plant-based, raw when possible, and deeply nourishing. There is no wellness plan—guests are invited to tune in, follow instinct, and release performance mode.
While AZULIK doesn't offer diagnostics or structure, the impact is significant. Artists, founders, and those in emotional transition often experience creative breakthroughs, emotional clarity, and a complete shift in perspective. The absence of technology acts as a fast-track for nervous system regulation.
AZULIK TULUM - Analog Rituals and Intuitive Reset in the Jungle
These retreats are responding to real needs—fatigue, systemic inflammation, stress overload, and digital burnout. What they offer goes beyond treatment. They provide rhythm, clarity, and frameworks that allow the body and mind to restore function. Each one encourages a deeper presence, a stronger sense of agency, and an updated understanding of what real vitality feels like.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
Yahoo
13 hours ago
- Yahoo
🚨 Ter Stegen undergoes successful surgery, return date still unknown
The operation of Marc André Ter Stegen has been confirmed. The FC Barcelona goalkeeper underwent surgery this Tuesday to address his lumbar issues. "The first team player Marc Ter Stegen has successfully undergone surgery again for his lumbar problems by Dr. Amélie Léglise, under the supervision of the Club's Medical Services, at the Sports Clinic Bordeaux Merignac. He is out and his recovery will determine his availability", reads the Barça statement. The club has not provided information regarding his recovery time. This has sparked a debate focusing on the situation of the Barça goalkeeping position. The difficulties in registering Joan García have prompted discussions on how many months Ter Stegen will be sidelined. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 Alex Grimm - 2025 Getty Images
Yahoo
13 hours ago
- Yahoo
Sarepta can begin shipping Elevidys therapy after FDA reverses pause, stock soars
Sarepta (SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug Administration (FDA) reversed its request for a voluntary pause late Monday. The news sent Sarepta's stock up sharply. The company extended gains Tuesday, with its stock up more than 40% in pre-market action. Sarepta had been trading down nearly 90% year-to-date after four patient deaths, and FDA probe and a European Medicines Agency panel recommending rejection of Elevidys pressured the company last week. "We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of Elevidys for ambulatory patients," said Sarepta CEO Doug Ingram, in a statement Monday. The FDA will continue to investigate the patient deaths, the latest of which was a 51-year-old patient in a clinical trial for a different muscular dystrophy drug. There was also an 8-year-old boy in Brazil, who died on June 7 from a different drug. There have been two Elevidys patient deaths reported this year. Analysts are cautiously optimistic about the shipments resuming, but are waiting to see the impact to the bottom line. The company has needed to continue strong sales of Elevidys in order to clear its $1.5 billion convertible debt due in 2027. "It seems like the FDA is listening to the community and this is great news for patients, but we remain on the sidelines until we gain better visibility into how demand trends, which is important from a balance sheet perspective," wrote Leerink Partners analyst Joseph Schwartz in a note to clients Monday. Jefferies analyst Andrew Tsai, one of the few which had maintained a Buy rating on the stock, said his firm did not doubt the company's ability to get the product back on the market, and is now watching how sales follow. "We were already unsure whether FDA could pull our premise was that Elevidys stays on the market ... though we also acknowledge Elevidys' sales outlook was looking murkier when SRPT went against the FDA's wishes (i.e. hospitals were starting to pause dosing)," Tsai wrote. "If SRPT's internal stress tests of the... franchise 'flooring' at $1.4B annually into the Street might have greater confidence in SRPT's ability to pay off the $1.1B+ of converts in 2027," he added. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
